- Home
- BHF vs NAMS Comparison
BHF vs NAMS Comparison
Compare BHF & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHF | NAMS |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BHF | NAMS |
|---|---|---|
| Price | $60.72 | $34.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $57.71 | $46.75 |
| AVG Volume (30 Days) | 508.4K | ★ 794.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.59 | $17.96 |
| Revenue Next Year | $1.82 | $540.65 |
| P/E Ratio | $4.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.16 | $14.92 |
| 52 Week High | $66.33 | $42.00 |
Technical Indicators
Market Signals| Indicator | BHF | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 61.80 |
| Support Level | $59.03 | $34.05 |
| Resistance Level | $60.76 | $37.43 |
| Average True Range (ATR) | 0.69 | 1.69 |
| MACD | 0.21 | 0.59 |
| Stochastic Oscillator | 75.69 | 90.80 |
Price Performance
Historical ComparisonAbout BHF Brighthouse Financial Inc.
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.